Business
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming
About this update from Enlivex Ltd.
[{"type":"text","content":"Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the European Patent Office has issued European patent No. 3,258,943 covering AllocetraTM, the Company’s immunotherapy product candidate. The new patent’s title is “COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT”, and is expected to provide added intellectual property protection for therapeutic compositions of AllocetraTMand CAR-T immunotherapies for inhibition or reduction ofcytokine storms associated with CAR-T therapies for cancer. Oren Hershkovitz, PhD, CEO of Enlivex, stated, “We are pleased to have this patent granted in Europe, which adds to existing AllocetraTM patents in various countries around the world. Specifically, this new patent further strengthens our existing intellectual property portfolio covering the use of AllocetraTM for cancer therapy.” AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents. ABOUT ENLIVEX Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com. Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could...